2wor Citations

Identification and characterization of binding sites on S100A7, a participant in cancer and inflammation pathways.

Biochemistry 48 10591-600 (2009)
Cited: 16 times
EuropePMC logo PMID: 19810752

Abstract

S100A7 (psoriasin) is a member of the S100 family of signaling proteins. It is implicated in and considered a therapeutic target for inflammation and cancer, yet no small molecule ligands for S100A7 have been identified. To begin the development of specific small molecule inhibitors of S100A7 function, we have used a series of surface binding fluorescent dyes to probe the surface hydrophobic sites. Two naphthalene-based dyes (2,6-ANS and 1,8-ANS) were found to bind S100A7 in a distinct cleft. We characterized the binding interaction by determining both the structure of S100A7 bound to 2,6-ANS and the structure of S100A7 bound to 1,8-ANS to 1.6 A. In both cases, two molecules of dye were docked such that the naphthalene groups were positioned in two symmetry-related grooves that are formed by the N-terminal helices of each monomer. We observed that Met12 acts as a gatekeeper to the binding cleft, adopting an "open" conformation for the more elongated 2,6-ANS while remaining in a "closed" conformation for the more compact 1,8-ANS. Steady-state fluorescence experiments revealed that S100A7 binds two copies of 2,6-ANS, each with a K(d) of 125 muM. Time-resolved fluorescence lifetime measurements indicated that the two molecules of 2,6-ANS bind in two independent binding sites with different fluorescence lifetimes, suggesting that the S100A7 homodimer is not perfectly symmetric in solution. Isothermal titration calorimetry studies demonstrate that S100A7 has a higher affinity for 2,6-ANS than 1,8-ANS. Yeast two-hybrid studies were also used to probe contributions of individual residues of an S100A7 triple mutant with respect to Jab1 binding. Mutation of Leu78, which forms part of the Met12 cleft occupied by 2,6-ANS, reduced the level of Jab1 binding, suggesting a potentially important role for the Met12 hydrophobic pocket in defining a Jab1 interface. Additional Y2H studies also delineate contributions of Gln88 and in particular Asp56 that shows the most significant abrogated binding to Jab1. Collectively, these data suggest a complex interaction between S100A7 and the much larger Jab1. These studies form the basis for the development of small molecule reporters and modifiers of S100A7 form and function.

Articles - 2wor mentioned but not cited (2)

  1. Multiple Evolutionary Origins of Ubiquitous Cu2+ and Zn2+ Binding in the S100 Protein Family. Wheeler LC, Donor MT, Prell JS, Harms MJ. PLoS One 11 e0164740 (2016)
  2. Conservation of Specificity in Two Low-Specificity Proteins. Wheeler LC, Anderson JA, Morrison AJ, Wong CE, Harms MJ. Biochemistry 57 684-695 (2018)


Reviews citing this publication (4)

  1. Binding of transition metals to S100 proteins. Gilston BA, Skaar EP, Chazin WJ. Sci China Life Sci 59 792-801 (2016)
  2. Survey of the year 2009: applications of isothermal titration calorimetry. Falconer RJ, Collins BM. J Mol Recognit 24 1-16 (2011)
  3. Role of the S100 protein family in rheumatoid arthritis. Wu YY, Li XF, Wu S, Niu XN, Yin SQ, Huang C, Li J. Arthritis Res Ther 24 35 (2022)
  4. RAGE Inhibitors for Targeted Therapy of Cancer: A Comprehensive Review. Faruqui T, Khan MS, Akhter Y, Khan S, Rafi Z, Saeed M, Han I, Choi EH, Yadav DK. Int J Mol Sci 24 266 (2022)

Articles citing this publication (10)

  1. Nuclear S100A7 is associated with poor prognosis in head and neck cancer. Tripathi SC, Matta A, Kaur J, Grigull J, Chauhan SS, Thakar A, Shukla NK, Duggal R, DattaGupta S, Ralhan R, Siu KW. PLoS One 5 e11939 (2010)
  2. S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia. Kaur J, Matta A, Kak I, Srivastava G, Assi J, Leong I, Witterick I, Colgan TJ, Macmillan C, Siu KW, Walfish PG, Ralhan R. Int J Cancer 134 1379-1388 (2014)
  3. Psoriasin (S100A7) associates with integrin β6 subunit and is required for αvβ6-dependent carcinoma cell invasion. Morgan MR, Jazayeri M, Ramsay AG, Thomas GJ, Boulanger MJ, Hart IR, Marshall JF. Oncogene 30 1422-1435 (2011)
  4. cPLA2 blockade attenuates S100A7-mediated breast tumorigenicity by inhibiting the immunosuppressive tumor microenvironment. Mishra S, Charan M, Shukla RK, Agarwal P, Misri S, Verma AK, Ahirwar DK, Siddiqui J, Kaul K, Sahu N, Vyas K, Garg AA, Khan A, Miles WO, Song JW, Bhutani N, Ganju RK. J Exp Clin Cancer Res 41 54 (2022)
  5. Structural characterization of S100A15 reveals a novel zinc coordination site among S100 proteins and altered surface chemistry with functional implications for receptor binding. Murray JI, Tonkin ML, Whiting AL, Peng F, Farnell B, Cullen JT, Hof F, Boulanger MJ. BMC Struct Biol 12 16 (2012)
  6. Application of ANS fluorescent probes to identify hydrophobic sites on the surface of DREAM. Gonzalez WG, Miksovska J. Biochim Biophys Acta 1844 1472-1480 (2014)
  7. S100A7, Jab1, and p27kip1 expression in psoriasis and S100A7 CRISPR-activated human keratinocyte cell line. Granata M, Skarmoutsou E, Gangemi P, Mazzarino MC, D'Amico F. J Cell Biochem 120 3384-3392 (2019)
  8. Thermodynamic analysis of ANS binding to partially unfolded α-lactalbumin: correlation of endothermic to exothermic changeover with formation of authentic molten globules. Kim KH, Yun S, Mok KH, Lee EK. J Mol Recognit 29 446-451 (2016)
  9. Structural and functional characterization of a triple mutant form of S100A7 defective for Jab1 binding. West NR, Farnell B, Murray JI, Hof F, Watson PH, Boulanger MJ. Protein Sci 18 2615-2623 (2009)
  10. Asthma-protective agents in dust from traditional farm environments. Marques Dos Santos M, Pivniouk V, Rankl B, Walker A, Pagani G, Hertkorn N, Schmitt-Kopplin P, Müller C, Bracher F, Merl-Pham J, Hauck SM, Schloter M, Michael AN, Anderson D, Honeker L, Gozdz J, Pivniouk O, Ober C, Holbreich M, Martinez FD, Snyder SA, von Mutius E, Vercelli D. J Allergy Clin Immunol 152 610-621 (2023)